RT Journal Article
SR Electronic
T1 Causal effect of adiposity on the risk of 19 gastrointestinal diseases: a Mendelian randomization study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.19.21266578
DO 10.1101/2021.11.19.21266578
A1 Min Seo Kim
A1 Minku Song
A1 Soyeon Kim
A1 Beomsu Kim
A1 Wonseok Kang
A1 Jong Yeob Kim
A1 Woojae Myung
A1 Inhyeok Lee
A1 Ron Do
A1 Amit V Khera
A1 Hong-Hee Won
YR 2021
UL http://medrxiv.org/content/early/2021/11/19/2021.11.19.21266578.abstract
AB Objectives We applied Mendelian randomization (MR) to investigate the causal associations of body mass index (BMI) and waist circumference (WC) with 19 gastrointestinal (GI) disorders.Design MR study.Setting The UK Biobank, Genetic Investigation of Anthropometric Traits (GIANT) Consortium, FinnGen consortium, and genome-wide association studies.Participants Overall, >400,000 UK Biobank participants, >170,000 participants of Finnish descent, and numerous consortia participants with predominantly European ancestry.Interventions Single-nucleotide polymorphisms associated with BMI and WC were used as instrumental variables to estimate the causal associations with the GI conditions.Main outcome measures Risk of developing 19 GI diseasesResults After correction for multiple testing (Bonferroni-corrected threshold of P<0.05/19) and testing for consistencies using several MR methods with varying assumptions (inverse variance weighted, weighted median, MR-Egger, and MR-PRESSO), genetically predicted BMI was associated with increased risks of non-alcoholic fatty liver disease (NAFLD), cholecystitis, cholelithiasis, and primary biliary cholangitis. The odds ratio (OR) per one standard deviation (SD) increased in genetically predicted BMI (4.77 kg/m2) from 1.22 (95% confidence interval [CI] 1.12–1.34; P<0.0001) for NAFLD to 1.65 (95% CI 1.31–2.06; P<0.0001) for cholecystitis. Genetically predicted WC was associated with increased risks of NAFLD, alcoholic liver disease (ALD), cholecystitis, cholelithiasis, colon cancer, and gastric cancer. ALD was associated with WC even after adjustment for alcohol consumption in multivariable MR analysis. The OR per 1 SD increased in genetically predicted WC (12.52 cm) from 1.41 (95% CI 1.17–1.70; P=0.0015) for gastric cancer to 1.74 (95% CI 1.21–1.78; P<0.0001) for cholelithiasis.Conclusions Higher BMI and WC are causally associated with an increased risk of GI abnormalities, particularly of hepatobiliary organs (liver, biliary tract, and gallbladder) that are functionally related to fat metabolism. Abdominal obesity measured by WC might be more influential and relevant with a diverse span of GI diseases than BMI, highlighting a possible pathophysiological role of visceral abdominal fats in the development of GI disorders and cancers.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (no. 2019R1A2C4070496). Dr. Do is supported by the National Institute of General Medical Sciences of the NIH (R35-GM124836) and the National Heart, Lung, and Blood Institute of the NIH (R01-HL139865 and R01-HL155915). H Won had full access to all data in the study. H Won made the final decision to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:GWAS catalog, UK BiobankI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript